One critical barrier in efforts to control the COVID-19 pandemic has been the relatively high false-negative rate of the most commonly-used Reverse Transcription Polymerase Chain Reaction (RT-PCR) testing methods.
Often, these methods are not able to detect lower viral loads, which are typically present in asymptomatic individuals but below the limit of detection (LoD) of standard one- or two-step RT-PCR methods. Researchers from NYU Abu Dhabi’s Biology Program and Center for Genomics and Systems Biology (CGSB) have implemented a new three-step testing approach that promises to significantly – and cost-effectively -- improve testing accuracy.
Rather than combining the RT and qPCR reactions, the NYUAD researchers, led by Professor of Biology at NYU and NYUAD Kris Gunsalus and Assistant Professor of Biology at NYUAD Youssef Idaghdour employed a technique involving sequential RT, cDNA preamplification, and qPCR, using a microfluidics platform.
The researchers demonstrated reliable ultra-sensitive and quantitative detection of low SARS-CoV-2 viral loads (less than one copy/microliter) using synthetic viral RNA, clinical nasopharyngeal swab samples and saliva samples, including samples previously diagnosed as negative by clinical diagnostic testing. Their findings, reported in the journal Processes are that this microfluidic RT-PCR assay is a sensitive, quantitative, and cost-effective detection strategy which could markedly reduce the false negative rate of clinical diagnostic tests – a potentially valuable tool in SARS-CoV-2 active screening and early detection programs.
